UrologySchool.com

Stones: Diet and Pharmacologic Management: Difference between revisions

← Older edit
VisualWikitext
 
Line 176: Line 176:
**Acetazolamide, a carbonic anhydrase inhibitor, leads to an increase in urinary bicarbonate and increased H+ reabsorption.
**Acetazolamide, a carbonic anhydrase inhibitor, leads to an increase in urinary bicarbonate and increased H+ reabsorption.
**Up to 50% of patients may discontinue acetazolamide due to adverse effects.
**Up to 50% of patients may discontinue acetazolamide due to adverse effects.
===Uric acid and cystine stones===
*'''<span style="color:#ff0000">Potassium citrate should be offered to patients with uric acid and cystine stones to raise urinary pH to an optimal level</span>'''
**'''For uric acid stone formers, a urine pH of 6.0 (CUA targets 6.5)''' '''should be achieved'''
**'''For cystine stone formers, a urine pH of 7.0 (CUA targets >7.0) should be achieved'''
===Cystine stones===
===Cystine stones===
*'''<span style="color:#ff0000">First-line therapy for patients with cystine stones:</span>'''
*'''<span style="color:#ff0000">First-line therapy for patients with cystine stones:</span>'''
Retrieved from "https://urologyschool.com/wikiuro/index.php/Stones:_Diet_and_Pharmacologic_Management"